Alpha-synuclein inhibitors - Pipeline Insight, 2024

This “Alpha-Synuclein Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Alpha-Synuclein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Alpha-Synuclein Inhibitors Understanding

Alpha-Synuclein Inhibitors: Overview

a-Synuclein is a highly soluble unfolded protein that accumulates in Lewy bodies and Lewy neurites in Parkinson disease and other synucleinopathies. It is abundant in the brain, while smaller amounts are found in the heart, muscle and other tissues. In the brain, alpha-synuclein is found mainly at the tips of neurons in specialized structures called presynaptic terminals

Function - Although the function of alpha-synuclein is not well understood, studies suggest that it plays a role in restricting the mobility of synaptic vesicles, consequently attenuating synaptic vesicle recycling and neurotransmitter release. An alternate view is that alpha-synuclein binds to VAMP2 (a synaptobrevin) and stabilizes SNARE complexes; though recent studies indicate that alpha-synuclein-VAMP2 binding is critical for alpha-synuclein-mediated attenuation of synaptic vesicle recycling, connecting the two seemingly divergent views. It may also help regulate the release of dopamine, a type of neurotransmitter that is critical for controlling the start and stop of voluntary and involuntary movements.

Alpha-Synuclein Inhibitors - Synucleinopathies are a group of disorders characterized by the accumulation of a-Synuclein amyloid inclusions in the brain. Preventing a-Synuclein aggregation is challenging because of the disordered nature of the protein and the stochastic nature of fibrillogenesis, but, at the same time, it is a promising approach for therapeutic intervention in these pathologies.

Alpha-Synuclein Inhibitors Emerging Drugs Chapters

This segment of the Alpha-Synuclein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alpha-Synuclein Inhibitors Emerging Drugs

R-phenserine: Annovis BioR -phenserine is a R-enantiomer (positive isomer) of phenserine, being developed by Annovis Bio (formerly QR Pharma), under a licence from Horizon Therapeutics plc (formerly Horizon Pharma), for the treatment of Alzheimer's disease (AD) and dementia in Down syndrome (AD-DS), Parkinson's disease (PD), stroke and traumatic brain injuries. Currently, it is in phase 2 stage of development for the treatment of Mild cognitive impairment.

UCB 0599: UCB BiopharmaUCB0599 is an orally bioavailable, brain barrier penetrant small molecule that prevents the oligomerization of alpha-synuclein. Alpha-synuclein oligomerization and aggregation is implicated in Parkinson’s disease and other degenerative diseases. By inhibiting misfolding and oligomerization of alpha-synuclein, it is believed that the progression of Parkinson’s disease can be slowed or halted. UCB0599 belongs to a series of molecules discovered by Neuropore, which were licensed to UCB in 2014. Currently, it is in phase 2 stage of development for the treatment of Parkinson's disease.

Alpha-Synuclein Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Alpha-Synuclein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Alpha-Synuclein Inhibitors

There are approx. 15+ key companies which are developing the Alpha-Synuclein Inhibitors. The companies which have their Alpha-Synuclein Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Annovis Bio.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Alpha-Synuclein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alpha-Synuclein Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha-Synuclein Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha-Synuclein Inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Alpha-Synuclein Inhibitors R&D. The therapies under development are focused on novel approaches for Alpha-Synuclein Inhibitors.

Alpha-Synuclein Inhibitors Report Insights

• Alpha-Synuclein Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Alpha-Synuclein Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Alpha-Synuclein Inhibitors drugs?
• How many Alpha-Synuclein Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Alpha-Synuclein Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Alpha-Synuclein Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Alpha-Synuclein Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Annovis Bio
• UCB Biopharma
• Alterity Therapeutics
• Denali Therapeutics Inc
• Lundbeck A/S
• AbbVie
• Prevail Therapeutics
• United Neuroscience
• AstraZeneca
• Nitrome Biosciences
• Enterin
• AFFiRiS
• Prothena Corporation
• Roche
• Proclara Biosciences
• Modag
• ProMIS Neurosciences

Key Products

• R-phenserine
• UCB 0599
• ATH 434
• ATV:aSyn
• Lu AF82422
• ABBV 0805
• PR 004
• UB 312
• MEDI 1341
• ENT 01
• Affitope PD01
• Affitope PD03
• Prasinezumab
• NPT 189
• anle 138b

This product will be delivered within 1-3 business days.